These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18044689)

  • 21. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.
    Cazzola M; Santus P; Di Marco F; Boveri B; Castagna F; Carlucci P; Matera MG; Centanni S
    Respir Med; 2003 May; 97(5):453-7. PubMed ID: 12735659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
    Price D; Keininger D; Costa-Scharplatz M; Mezzi K; Dimova M; Asukai Y; Ställberg B
    Respir Med; 2014 Dec; 108(12):1786-93. PubMed ID: 25307414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives.
    Mittmann N; Hernandez P; Mellström C; Brannman L; Welte T
    Pharmacoeconomics; 2011 May; 29(5):403-14. PubMed ID: 21504240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.
    Oba Y
    Am J Manag Care; 2009 Apr; 15(4):226-32. PubMed ID: 19355795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA.
    Stanford RH; Parker ED; Reinsch TK; Buikema AR; Blauer-Peterson C
    Respir Med; 2019 Apr; 150():1-7. PubMed ID: 30961933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma.
    Aalbers R; Backer V; Kava TT; Omenaas ER; Sandström T; Jorup C; Welte T
    Curr Med Res Opin; 2004; 20(2):225-40. PubMed ID: 15006018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma.
    Pieters WR; Wilson KK; Smith HC; Tamminga JJ; Sondhi S
    Treat Respir Med; 2005; 4(2):129-38. PubMed ID: 15813665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pitfalls associated with the therapeutic reference pricing practice of asthma medication.
    Kalo Z; Abonyi-Toth Z; Bartfai Z; Voko Z
    BMC Pulm Med; 2012 Jul; 12():35. PubMed ID: 22818402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma.
    Markham A; Adkins JC
    Pharmacoeconomics; 2000 Dec; 18(6):591-608. PubMed ID: 11227397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases.
    Sin DD; Man SF
    Eur J Pharmacol; 2006 Mar; 533(1-3):28-35. PubMed ID: 16457807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2003; 21(13):951-89. PubMed ID: 12959627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seretide: a pharmacoeconomic analysis.
    Fritscher L; Chapman KR
    J Med Econ; 2008; 11(3):555-70. PubMed ID: 19450105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries.
    Lewis A; Torvinen S; Dekhuijzen PN; Chrystyn H; Watson AT; Blackney M; Plich A
    BMC Health Serv Res; 2016 Jul; 16():251. PubMed ID: 27406133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal.
    Reza Maleki-Yazdi M; Molimard M; Keininger DL; Gruenberger JB; Carrasco J; Pitotti C; Sauvage E; Chehab S; Price D
    Appl Health Econ Health Policy; 2016 Oct; 14(5):579-94. PubMed ID: 27516088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective database study comparing treatment outcomes and cost associated with choice of fixed-dose inhaled corticosteroid/long-acting beta-agonists for asthma maintenance treatment in Germany.
    Aballéa S; Cure S; Vogelmeier C; Wirén A
    Int J Clin Pract; 2008 Dec; 62(12):1870-9. PubMed ID: 18803555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD.
    Najafzadeh M; Marra CA; Sadatsafavi M; Aaron SD; Sullivan SD; Vandemheen KL; Jones PW; Fitzgerald JM
    Thorax; 2008 Nov; 63(11):962-7. PubMed ID: 18621985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of combination therapy for chronic obstructive pulmonary disease.
    Chuck A; Jacobs P; Mayers I; Marciniuk D
    Can Respir J; 2008; 15(8):437-43. PubMed ID: 19107245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy.
    Price D; Wirén A; Kuna P
    Allergy; 2007 Oct; 62(10):1189-98. PubMed ID: 17845590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and economic outcomes in an observational study of COPD maintenance therapies: multivariable regression versus propensity score matching.
    Roberts MH; Dalal AA
    Int J Chron Obstruct Pulmon Dis; 2012; 7():221-33. PubMed ID: 22500122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Spencer S; Evans DJ; Karner C; Cates CJ
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.